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Abstract 27 
Nucleus pulposus (NP) replacement offers a minimally invasive alternative to spinal 28 
fusion or total disc replacement for the treatment of intervertebral disc (IVD) 29 
degeneration. This study aimed to develop a cytocompatible NP replacement 30 
material, which is feasible for non-invasive delivery and tunable design, and allows 31 
immediate mechanical restoration of the IVD. A bi-phasic polyurethane scaffold was 32 
fabricated consisting of a core material with rapid swelling property and a flexible 33 
electrospun envelope. The scaffold was assessed in a bovine whole IVD organ 34 
culture model under dynamic load for 14 days. Nucleotomy was achieved by incision 35 
through the endplate without damaging the annulus fibrosus. After implantation of the 36 
scaffold and in situ swelling, the dynamic compressive stiffness and disc height were 37 
restored immediately. The scaffold also showed favorable cytocompatibility for native 38 
disc cells. Implantation of the scaffold in a partially nucleotomized IVD down-39 
regulated catabolic gene expression, increased proteoglycan and type II collagen 40 
intensity and decreased type I collagen intensity in remaining NP tissue, indicating 41 
potential to retard degeneration and preserve the IVD cell phenotype. The scaffold 42 
can be delivered in a minimally invasive manner, and the geometry of the scaffold 43 
post-hydration is tunable by adjusting the core material, which allows individualized 44 
design.   45 
 46 
Keywords 47 
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Introduction 52 
The intervertebral disc (IVD) is a complex tissue structure with important mechanical 53 
functions. It consists of a central part, the nucleus pulposus (NP), the surrounding 54 
annulus fibrosus (AF), and the cartilaginous endplates which provide the permeable 55 
connections to the bony vertebrae. The main function of the NP is to absorb and 56 
distribute mechanical load exerted on the spinal column. To fulfil this function, the NP 57 
contains specific extracellular matrix components rich in proteoglycans that allow the 58 
maintenance of a highly hydrated state and high swelling pressure [1]. 59 
IVD degeneration is associated with changes in extracellular matrix composition that 60 
often have biomechanical consequences and can lead to painful and debilitating 61 
conditions. The resulting neck and low back pain are major determinants of 62 
discomfort and disability and are the origin of enormous socio-economic health care 63 
problems worldwide [2-4]. Treatment methods range from physical therapies and 64 
pain relieving medication to highly invasive surgical procedures. Discectomy is often 65 
performed in cases of disc bulging or herniation to relieve the painful pressure on 66 
neural elements. Spinal fusion is another standard treatment intended to relieve pain 67 
by reducing motion across the joint. However, removal of disc tissue and fusion alter 68 
the biomechanical function and can accelerate IVD degeneration at adjacent levels 69 
[5]. Due to the limited healing potential and harsh nutritional conditions of adult IVDs, 70 
loss or failure of the extracellular matrix is virtually irreversible and requires 71 
restoration. Implants for total IVD replacement have been developed in order to 72 
preserve the motion at the operated level. However, the procedure is highly invasive 73 
and may not be appropriate at early stages of degeneration; in addition the long term 74 
effects are still uncertain [6].  75 
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Functionally, during IVD degeneration the NP becomes dehydrated, is replaced by 76 
fibrous tissue, and loses its high osmotic pressure [2, 7, 8]. The severe loss of water 77 
content in the NP also causes a reduction in disc height. NP replacement therapy has 78 
therefore been proposed as a less invasive alternative method to spinal fusion or 79 
total IVD replacement [9]. An ideal NP replacement material would allow immediate 80 
redistribution of loads and restoration of disc height, while maintaining the flexibility of 81 
the spine. Various synthetic polymeric materials have been described as potential NP 82 
substitutes that may be delivered as injectable hydrogel or pre-formed material [10-83 
13]. However, several concerns still exist in their application. While conventional 84 
injectable hydrogels can be delivered through the AF in a minimally-invasive manner, 85 
their generally weak mechanical properties do not allow direct restoration of the disc 86 
height and mechanical function; in addition, their three-dimensional structure is 87 
difficult to control and there is a substantial risk of material leakage with adverse 88 
effects. Pre-formed polymers and scaffolds have the advantage of improved 89 
structural control and faster response to external mechanical forces. Nevertheless, 90 
their application requires a more invasive procedure, and unwanted outcomes such 91 
as material displacement may occur [14-16]. 92 
The polyurethane (PU) family of biomaterials has been introduced for medical use 93 
because of their elastomeric properties. By varying the composition of the monomer 94 
units and the size of the blocks of the dissimilar monomers within the polymer chain, 95 
these properties can be tailored. As such, PU has been used in applications in which 96 
an elastomeric material is likely to enhance the success or longevity of the implant. 97 
Specifically, PU has been used in cardiovascular applications, where material 98 
flexibility is important, such as for catheters, insulations, vascular prostheses, heart 99 
valves or assist devices [17]. Furthermore, a range of tissue replacement or 100 
augmentation materials are based on PU, especially as wound dressing for skin 101 
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regeneration [18]. Among the PU family, polycarbonate urethanes have 102 
demonstrated improved biostability and are therefore preferred for many applications 103 
[19, 20]. The function of the intervertebral disc relies on the elastomeric nature of the 104 
matrix components and fluid of which they are constituted; hence, PU is an attractive 105 
material for IVD restoration. In fact PU based materials have been used in spinal 106 
surgery and the overall mechanical and biological properties indicate no long-term 107 
problems to date; though information on their application as pure NP replacement is 108 
scarce [21]. 109 
Taking into account the requirements for an NP substitute, we have developed a new 110 
bi-phasic polyurethane (PU) scaffold consisting of a highly hydrophilic core material 111 
with significant instant swelling capabilities and an electrospun envelope. The 112 
functions of the envelope are to assure the structural control of the implant after 113 
swelling in situ and to facilitate cell attachment and tissue integration to keep the 114 
implant stable also under mechanical load. Moreover, the unique flat geometry and 115 
flexible shape of the bi-phasic scaffold system allow minimally invasive administration 116 
into the NP of the IVD.  117 
The aim of this work was to assess the mechanical, swelling properties and the 118 
cytocompatibility of the scaffold materials. A whole IVD organ culture model was then 119 
used to test the hypothesis that the implanted scaffold could restore the disc height 120 
and mechanical stiffness in a nucleotomized IVD. Histological and gene expression 121 
analyses were performed to evaluate the biological response of the disc cells and 122 
tissues to the implanted scaffold.    123 
  124 
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Materials and Methods 125 
1. Fabrication and characterization of PU scaffolds 126 
1.1. Fabrication of PU scaffolds 127 
PU scaffolds with swelling capability were manufactured to obtain implants with a flat 128 
discoid structure. The scaffolds are composed of a core film which swells to a 129 
hydrogel following contact with an aqueous medium, and an envelope composed of 130 
electrospun polymer mixture with a fibrous mat structure (Fig. 1 A). The core solution 131 
was prepared with the ether-based hydrophilic urethane HydroMed™ (HM, 132 
AdvanSource Biomaterials), which was dissolved at a concentration of 20 % (w/w) in 133 
95% ethanol (Bio-Lab) by stirring overnight at room temperature. A predetermined 134 
solution volume was casted on a flat glass plate, dried for three days to ensure 135 
solvent residues evaporation and then cut into discs at a diameter of 3, 5 and 8 mm 136 
for manufacturing scaffold at external diameter of 6, 8 or 9, and 14 mm, respectively. 137 
For production of the envelope a mixture was prepared by combining the 138 
polycarbonate urethanes Chronoflex™ (CF, AdvanSource Biomaterials) and HM. In 139 
order to select the optimal ratio of CF to HM in the envelope formulation, several 140 
ratios were tested. Wetting time was visually inspected until color change observed 141 
and mechanical property was evaluated by measurement of the tensile strength. As 142 
shown in Table 1, addition of HM to CF resulted in decrease in the mechanical 143 
strength and reduced the wetting time. Optimal balance between wetting, mechanical 144 
strength and manufacturing considerations by electrospinning resulted in the 145 
selection of CF:HM w/w ratio at 10:1. The polyurethane mixture was then dissolved at 146 
a concentration of 13% (w/w) in a solvent mixture of 1:2 w/w N-N-dimethylformamide 147 
(BioLab) and dioxane (BioLab). Electrospun envelope structures at a thickness of 148 
200 μm were fabricated according to specifications for strong fibers at a range of 0.5-149 
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2 µm and porosity of ~70%. The following electrospinning parameters were applied at 150 
an environment of 40% relative humidity and 28°C. A collector at diameter of 50 mm 151 
and length of 150 mm with rotating speed (ω) of 120 rpm was used. A five needles 152 
spinneret was used (22 G, 25 mm length) at linear speed of 57 mm/sec and traverse 153 
shuttle of 170 mm. The spinneret was placed 260 mm from the collector. A potential 154 
of 60 kV, solution flow rate of 14 mL/h and consumption of 10 mL were applied.  155 
Following electrospinning the envelope sheet was dried overnight at room 156 
temperature and then at 50±5°C for 48 hours. The dried envelope sheets were cut 157 
into discs of 20 mm diameter before scaffold assembly.  158 
Core discs at predetermined content (see 1.3) and size were wrapped by two 159 
envelope discs that were heat sealed using custom made tools (Fig. 1 B). The 160 
sealing conditions were 4 seconds at pressure of 3 bar and temperature of 118°C. 161 
The PU scaffold was then cut into its final size, at a diameter of 6, 8, 9 or 14 mm. The 162 
scaffolds were sterilized in a cold-cycle (37°C) ethylene oxide process and 163 
subsequently evacuated at room temperature and 150 mbar for 7 days. 164 
A delivery system for non-invasive injection of the PU scaffolds was developed by 165 
Melab Medizintechnik und Labor GmbH (Germany). The PU scaffolds at diameters of 166 
6-14 mm can be rolled into a tube of 2.8-5 mm diameter and delivered through a 167 
needle with insertion guide. A demonstration of the delivery process is shown in 168 
Figure 1 C. 169 
 170 
1.2. Structure characterization of the PU scaffold envelope 171 
The electrospun envelope sheet material was examined using scanning electron 172 
microscopy (SEM). Electron micrographs were recorded for both sides and cross 173 
sectional areas of the electrospun envelope. Samples were snap-frozen in liquid 174 
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nitrogen and fractured into 2 or more pieces to obtain a cross-sectional edge. 175 
Samples were then mounted onto metallic stubs and coated with gold (~1 nm; 176 
Q150T-ES sputter coater, Quorum, UK) and their morphology observed on a Nova 177 
Nano SEM (FEI, Netherlands; Everhart-Thornley Detector in field-free lens mode) at 178 
2,000x and 10,000x magnifications. Fiber dimensions were measured in Q-capture 179 
pro (QImaging, Canada) using the scale bar of the SEM micrograph as a reference 180 
for each image. Measurements were taken from three samples. Approximately 50 181 
fibers were randomly selected for each micrograph.  182 
 183 
1.3. Swelling capacity and kinetics of PU scaffolds 184 
PU scaffolds with a diameter of 14 mm containing various dry weights of core (14 to 185 
97 mg, n=18) were incubated in aqueous medium at room temperature for 24 hours. 186 
The swelling capacity was calculated by measurement of the scaffold dry weight 187 
before swelling and the scaffold wet weight after incubation. Results were expressed 188 
as % swelling of core and/or % weight gain of PU scaffold. Swelling capacities of PU 189 
scaffolds with diameter of 6, 8, 9, and 14 mm were also measured at fixed core 190 
content (3.4 mg and 4.5 mg for 6 mm PU scaffold, 12 mg for 8 mm and 9 mm PU 191 
scaffold, 40 mg for 14 mm PU scaffold). Swelling kinetics measurements were 192 
carried out with scaffolds with diameter of 6 and 14 mm using various core contents 193 
(3.4 mg, 4.5 mg and 6.3 mg for 6 mm PU scaffold, 30 mg, 40 mg and 60 mg for 14 194 
mm PU scaffolds) in order to determine the time to reach significant swelling. 195 
 196 
1.4. Cytocompatibility of PU scaffolds 197 
To assess the potential release of cytotoxic components that might have remained or 198 
developed from the scaffold production process or the sterilization method, core and 199 
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envelope discs were incubated in Dulbecco's Modified Eagle Medium (DMEM, with 200 
4.5 g/L glucose, Gibco, Paisley, UK) containing 100 U/mL penicillin and 100 μg/mL 201 
streptomycin (1% Pen/Strep) (all products from Gibco) at 37°C under normoxic 202 
condition. The conditioned medium was collected after 3, 5 and 7 days. Nucleus 203 
pulposus cells (NPCs) were isolated from 4-10 months old bovine caudal IVD and 204 
cultured with DMEM, 1% Pen/Strep, 10% fetal calf serum (FCS, Gibco) at 37°C 205 
under normoxic condition [22]. Human bone marrow aspirates were obtained with 206 
ethical approval from the Swiss cantonal authorities (KEK 188/10) and informed 207 
consent. Bone marrow derived mesenchymal stem cells (MSCs) were isolated by 208 
Ficoll cushion and expanded with alpha modification of Eagle's medium (aMEM, 209 
Gibco), 1% Pen/Strep, 10% FCS, 5 ng/mL recombinant human basic fibroblast 210 
growth factor (Fitzgerald, Acton, USA) at 37°C under normoxic condition [23]. 211 
Passage 1 NPCs and passage 2 MSCs were seeded into 96-well plates and cultured 212 
in DMEM with 1% Pen/Strep, 2.5% FCS and 50% conditioned medium of PU core 213 
and envelope for 24 hours or 72 hours at 37°C under normoxic condition. Cell 214 
viability was determined with WST-1 cell proliferation reagent (Roche, Mannheim, 215 
Germany) according to an established protocol [24]. Cell viability of the samples was 216 
normalized to the positive control cells cultured in DMEM with 1% Pen/Strep and 2.5% 217 
FCS. 218 
A cell attachment study was performed to examine the capacity of the envelope to 219 
support cell attachment and growth. Passage 1 bovine NPCs were seeded on the top 220 
side of the envelope at a cell density of 100,000 cells per envelope (diameter 14 mm). 221 
Cell-envelope constructs were cultured in DMEM with 1% Pen/Strep and 10% FCS 222 
for 7 days at 37°C under normoxic condition. After 1 and 7 days of culture, samples 223 
were digested with 0.5 mg/mL proteinase-K (2.5 U/mg, Roche, Mannheim, Germany) 224 
at 56˚C overnight. DNA content was measured spectrofluorometrically using the 225 
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Picogreen assay (Invitrogen, Carlsbad, USA) to evaluate the cell proliferation. 226 
Samples were also prepared for SEM imaging of the top surfaces and cross-sections 227 
of the envelopes to evaluate the cell morphology and attachment on the material 228 
surface. Cell-seeded envelopes were fixed in 2.5% glutaraldehyde in 0.1 M PIPES 229 
buffer, and dehydrated in a series of graded concentrations of ethanol before critical 230 
point drying (Quorum Technologies Ltd, East Sussex, UK). Thereafter, samples were 231 
mounted on metallic stubs with silver paint, sputter coated with gold/palladium (10 nm) 232 
and imaged by SEM (Hitachi S-4700, Tokyo, Japan). 233 
 234 
2. IVD organ culture – IVD dissection, nucleotomy, PU scaffold implantation, and 235 
dynamic loading  236 
For assessment of the PU scaffold in organ culture which supplies a 237 
microenvironment close to the in vivo situation, bovine caudal spines (4-10 months) 238 
were obtained from local abattoirs and harvested aseptically within three hours after 239 
death. After removal of the soft tissue, IVDs were dissected by means of a band saw 240 
(model 30/833, Exakt Apparatebau, Norderstedt, Germany) proximal and distal to the 241 
cartilaginous endplates, and the endplates of each IVD were cleaned with a Pulsavac 242 
jet-lavage system (Zimmer, IN, USA) [22]. Initial disc height and diameter were 243 
recorded before IVDs were washed with PBS (pH 7.4) containing 10% Pen/Strep for 244 
15 min. Then IVDs were transferred to a six-well plate containing IVD culture medium 245 
and incubated overnight at 37°C, 85% humidity and 5% CO2. The IVD culture 246 
medium was composed of DMEM with 4.5 g/L glucose supplied with 2% FCS, 1% 247 
Pen/Strep, 1% ITS+ Premix (Discovery Labware, Inc., Bedford, USA), 50 μg/mL 248 
ascorbate-2-phosphate (Sigma-Aldrich, St. Louis, USA) and 0.1% Primocin. After 249 
dissection, the disc height of the bovine IVDs used for the current study ranged from 250 
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7 to 14 mm and the disc diameter ranged from 13 to 20 mm. IVDs from each tail were 251 
randomly assigned among experimental groups to obtain similar average disc size 252 
and distribution of disc levels for each group. 253 
A partial nucleotomy model [22] was used to mimic the clinical case of a large NP 254 
defect with relatively healthy non-degenerated surrounding disc tissue. To reach a 255 
nucleotomy fraction of approximately 50% of the total NP volume for different sizes of 256 
IVDs, a NP cavity with diameter of 4 mm was created in small IVDs with diameter of 257 
13-16.5 mm; in IVDs with diameter of 16.5-20 mm, a NP cavity with diameter of 6 mm 258 
was created. IVDs were nucleotomized through the endplate by central incisions with 259 
a biopsy punch of 4 or 6 mm diameter and a number 11 blade. After removing an 260 
endplate core, the NP tissue below the endplate core reaching until the distal 261 
endplate was excised. IVDs and endplate stoppers were preserved in gauze 262 
moistened with IVD culture media. Pilot experiments had revealed that dry PU 263 
scaffolds with 6 mm or 9 mm diameter obtained a diameter of 4 mm or 6 mm after 264 
hydration. Therefore, dry PU scaffolds with 6 mm or 9 mm diameter were implanted 265 
into the NP defects with 4 mm or 6 mm diameter, respectively. The PU scaffolds with 266 
a flat discoid structure were delivered into the NP cavity with forceps, and positioned 267 
parallel to the endplate of the IVD. After implantation of the dry PU scaffold, the 268 
removed endplate stopper was immediately re-inserted, and the crack between the 269 
stopper and the remaining endplate was sealed by polymethyl methacrylate (PMMA, 270 
Vertecem Mixing Kit, Synthes, Teknimed S.A., Bigorre, France) according to 271 
manufacturer’s instruction. For each IVD, approximately 100–150 mg of PMMA was 272 
applied. 273 
A bioreactor system was used to mimic physiologically relevant loading conditions of 274 
cultured IVDs [25]. IVDs were placed in custom-made chambers filled with 2 mL IVD 275 
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culture medium, and loaded dynamically for 3 hours/day at 0-0.1 MPa, 0.1 Hz. After 276 
dynamic loading IVDs were transferred to 6-well plates with 5 mL IVD culture medium 277 
for free swelling recovery overnight. It has been reported that the diurnal disc height 278 
loss of human lower lumbar discs was 11.1% [26]. Therefore, a 10% diurnal disc 279 
height loss was considered as physiological for organ cultured discs. In our previous 280 
study, this loading protocol applied on bovine caudal IVDs of similar age has shown 281 
to be physiologically relevant, as indicated by disc height loss and recovery at 282 
physiological level [27]. 283 
 284 
3. IVD organ culture - mechanical effect of PU scaffold implantation after 1 day of 285 
loading 286 
3.1. Experimental groups 287 
To investigate the mechanical repair effect of the PU scaffold, dynamic load was 288 
performed on partial nucleotomized IVDs implanted with PU scaffold (Scaffold group) 289 
for 3 hours. Empty IVDs served as negative controls (Empty group). The experiments 290 
were performed using IVDs from 6 bovine tails, with 2 IVDs from each tail randomly 291 
assigned to one of the two experimental groups.    292 
 293 
3.2. Dynamic compressive stiffness modulus  294 
Dynamic compressive stiffness modulus was measured for each IVD at the following 295 
time points: after dissection and overnight free swelling culture (intact), after partial 296 
nucleotomy (defect), after refilling with the PU scaffold and free swelling culture 297 
overnight (refilled), and after dynamic load and free swelling recovery. Measurement 298 
was performed using a custom-made chamber and a Bose 3220 instrument (Bose, 299 
MN, USA) as described previously [22]. IVDs were pre-loaded with 10% strain (based 300 
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on initial disc height after dissection) for 3 min, and then loaded with 10 cycles of 301 
sinusoidal compression at 5-15% of strain (based on initial disc height after 302 
dissection) at a frequency of 0.1 Hz for 100 seconds. Dynamic compressive stiffness 303 
modulus was calculated for each loading cycle as the stress segment divided by the 304 
strain segment (10%). Average value of 10 cycles was taken for each IVD at each 305 
time point. The stiffness modulus was then normalized to the value of respective 306 
intact IVD. 307 
 308 
3.3. Disc height change  309 
Disc height was measured with a caliper at the following time points: after dissection, 310 
after dissection and free swelling culture overnight (intact), after partial nucleotomy 311 
(defect), after refilling with biomaterial and free swelling culture overnight (refilled), 312 
after dynamic load, and after free swelling recovery. Each IVD was measured at four 313 
positions and the average value was used to calculate the percentage of disc height 314 
change. Disc height change was normalized to the initial dimension after dissection. 315 
 316 
4. IVD organ culture – mechanical and biological effects of PU scaffold 317 
implantation after 14 days of loading 318 
4.1. Experimental Groups 319 
The biological repair effect of the PU scaffold was investigated after 14 days of 320 
dynamic load. Empty IVDs served as negative controls. The experiments were 321 
performed using bovine IVDs from 12 tails, with 2 IVDs from each tail randomly 322 
assigned to one of the two experiment groups.    323 
 324 
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4.2. Disc height change  325 
The disc height was measured with a caliper at the following time points: day 0 after 326 
dissection, day 1 after 1st load, day 2 after 1st recovery, day 7 after 7th load, day 8 327 
after 7th recovery, day 14 after 14th load and day 15 after 14th recovery. Each IVD 328 
was measured at four positions and the average value was used to calculate the 329 
percentage of disc height change. Disc height change was normalized to the initial 330 
dimension after dissection. 331 
 332 
4.3. Biochemical and gene expression analysis  333 
After free swelling recovery on day 15 cartilaginous endplates of each IVD were 334 
removed and remaining NP and AF tissues were harvested by using a biopsy punch 335 
and a scalpel blade. Approximately 100 mg of each AF and NP tissue was used for 336 
RNA extraction; 50 mg of each AF and NP tissue was digested within 0.5 mg/mL 337 
proteinase K at 56°C overnight for glycosaminoglycan (GAG), collagen and DNA 338 
content measurement; 30 mg of NP tissue was used for [35S] sulfate incorporation 339 
assay to assess proteoglycan synthesis rate.  340 
For RNA extraction, tissue samples were flash frozen and pulverized in liquid 341 
nitrogen and homogenized using a TissueLyser (Qiagen, Venlo, Netherlands). Total 342 
RNA was extracted with TRI Reagent (Molecular Research Center) and reverse 343 
transcription was performed with SuperScript VILO cDNA Synthesis Kit (Life 344 
Technologies, Carlsbad, CA). Quantitative real-time PCR was performed using the 345 
Step-One-Plus instrument (Life Technologies). The sequences of custom designed 346 
bovine primers and TaqMan™ probes are shown in Table 2. For amplification of 18S 347 
ribosomal RNA (18S, 4310893E), Versican (Bt03217632_m1), and Biglycan (BGN, 348 
Bt03244532_m1), gene expression assays from Applied Biosystems (Life 349 
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Technologies) were used. Comparative Ct method was performed for relative 350 
quantification of target mRNA with 18S ribosomal RNA as endogenous control. 351 
The GAG content in the NP and AF tissues was determined by using the 1,9-352 
dimethylmethylene blue dye (DMMB) method [28]. Quantification of the total amount 353 
of collagen in NP and AF samples was performed using the hydroxyproline assay as 354 
described earlier [29]. DNA content was measured spectrofluorometrically using 355 
Hoechst (33258) dye.  356 
To determine the proteoglycan synthesis rate NP tissue was incubated for 16-20 357 
hours in IVD culture media supplemented with 2.5 µCi 35S-sulfate /mL (Na2 35SO4; 358 
PerkinElmer, Schwerzenbach, Switzerland). Thereafter NP tissue was digested with 359 
0.5 mg/mL proteinase K at 56°C overnight. Conditioned medium and proteinase K 360 
digested tissue samples were processed with PD-10 desalting columns (GE 361 
Healthcare, Glattbrugg, Switzerland) and radioactive counts were measured by 362 
Wallac 1414 Liquid Scintillation Counter (PerkinElmer, Schwerzenbach, Switzerland). 363 
The counts per minute (cpm) were normalized to the DNA content of the respective 364 
samples. 365 
 366 
4.4. Safranin O/Fast Green staining  367 
After free swelling recovery on day 15, whole IVDs with implanted PU scaffolds were 368 
fixed in 70% methanol and transferred into PBS with 5% sucrose at 4˚C overnight 369 
before cryosectioning. Transverse sections of IVDs were cut at a thickness of 12 µm. 370 
Sections were stained with 0.1% Safranin-O and 0.02% Fast Green to reveal 371 
proteoglycan and collagen deposition respectively, and counterstained with Weigert's 372 
Haematoxylin to reveal cell distribution. 373 
 374 
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4.5. Fourier transform infrared (FTIR) spectroscopic imaging 375 
After free swelling recovery on day 15, a set of IVDs (n=1 per group) were decalcified 376 
and subsequently embedded in paraffin. Four micrometre sagittal IVD sections were 377 
cut and mounted on custom made reflective 316 stainless steel slides for infrared 378 
analysis. FTIR microscopic images were collected using an Agilent 680-IR FTIR 379 
spectrometer (ISys50®, Malvern Instruments Limited, Worcestershire, UK) coupled 380 
to a FTIR imaging microscope fitted with a liquid nitrogen cooled 64 x 64 mercury-381 
cadmium-telluride focal plane array detector (FPA) and an automated sampling stage. 382 
For each sample, an area of 71 x 192 pixels (approximately 6.3 x 16.8 mm) was 383 
mapped in transflectance mode. Spectra were attained with a spectral resolution of 4 384 
cm-1 over a wavenumber range of 950-1900 cm-1. Data was pre-processed by 385 
performing a second derivative (Savitsky-Golay ISys50 software, Filter order 3, filter 386 
length 15) on the spectra to reduce baseline effects and assist the resolution of 387 
weaker absorption peaks [30]. Pixels within the tissue section where spectra 388 
indicated only the presence of paraffin or the substrate were identified and masked 389 
using spectral statistics (ISys50, histogram). Regions of interest (ROI; 10 x 192 pixels) 390 
across the middle of each sagittal section were cut and compiled to one data matrix. 391 
The data set was analyzed using a multivariate curve resolution-alternating least 392 
squares algorithm (MCR-ALS) described by Andrew and Hancewicz [31] and Wang 393 
et.al. [32]. MCR-ALS was carried out using the MCR-ALS v1.6 software (MCRv1.6 394 
Copyright © 2003-2004 Unilever) on two wavenumber regions of 950-1600 cm-1 and 395 
950-1300 cm-1 with the following settings; initial estimates: 4 -10F, NIPALS, ALS; 396 
ALS constraints: MALS-2D, none, 1e-005, 500. General tissue, collagen type I, 397 
collagen type II and proteoglycan distributions were estimated according to previous 398 
studies that have shown good agreement between (immuno-) histological staining 399 
and the integrated peak area of the 2nd derivative of the amide III spectral region 400 
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(1186-1297 cm-1) as well as MCR-ALS score maps [33]. Additionally, average matrix 401 
component per tissue distribution across ROIs were calculated and are represented 402 
as estimated component per tissue distribution line profiles across the normalized 403 
width (0-100%) of each IVD. 404 
 405 
5.  Statistical analysis 406 
SPSS 21.0 statistical software was used for statistical analysis. One sample 407 
Kolmogorov–Smirnov test was used to define whether the data were normally 408 
distributed (normal distribution at p > 0.1). For data that were normally distributed, 409 
unpaired T test was used to determine differences between Empty and Scaffold 410 
groups. For data that were not normally distributed, Mann-Whitney U was used to 411 
determine differences between Empty and Scaffold groups. A p-value <0.05 was 412 
considered statistically significant. 413 
 414 
Results 415 
1. Characterization of PU scaffold 416 
1.1. Structure characterization of PU scaffold envelope 417 
Randomly arranged, homogenous fibers could be observed in the SEM micrographs 418 
of electrospun PU scaffold envelopes, indicating a successful mixing and 419 
electrospinning of the Chronoflex and Hydromed mixture (Fig. 2). The generated 420 
fibers had an average thickness of 0.84 ± 0.52 µm. 421 
 422 
1.2. Swelling capacity and kinetics of PU scaffolds 423 
Swelling capacity of the scaffold (14 mm diameter) at various core contents is shown 424 
in Fig. 3. At the core content range tested, the swelling ratio of the scaffold increased 425 
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with the increase in core content. Swelling capacity of the different scaffold sizes and 426 
core amounts is summarized in Table 3. At the range tested, the core material 427 
reached similar swelling percentage (~800%) regardless of scaffold size. The 428 
scaffold weight gain increased with the increase in size.   429 
Swelling kinetics is shown in Fig. 4. The swelling rate was relatively fast after 430 
immersion in aqueous medium. In the case of the 14 mm scaffold, the scaffold 431 
swelling was about 500% of initial scaffold weight (~70-90% of maximum swelling) 432 
within one hour (Fig. 4 A). In the case of the 6 mm scaffold, the scaffold swelling, at 433 
all core contents tested, reached about 400% of initial scaffold weight (~90% of 434 
maximum swelling) already within one hour (Fig. 4 B). In all scaffolds tested, swelling 435 
in free environment reached more than 90% of maximum capacity within 8 hours. 436 
 437 
1.3. Cytocompatibility of PU scaffold component material 438 
Viable cell number after culture in the conditioned medium from both core and 439 
envelope material was >85% of control culture medium after up to 72 hours of culture 440 
for NPCs and MSCs (Fig. 5 A and B). Conditioned medium from core material 441 
supported MSC proliferation (viable cell number was above 160-180% of positive 442 
control after 72 hours culture), but did not affect NPC proliferation (viable cell number 443 
was 85-90% of positive control after 72 hours culture). 444 
DNA content of cell-envelope constructs after 1 day of culture showed that 88% of 445 
the seeded cells were attached to the envelope 24 hours after seeding, suggesting 446 
high cell attachment ratio. Compared with day 1, the DNA content of samples 447 
increased 4-fold after 7 days of culture, indicating active NPC proliferation on the 448 
envelope (data not shown). Representative SEM images also showed that cells 449 
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seeded on the top side of the envelope had proliferated and produced extracellular 450 
matrix after 7 days of culture (Fig. 5 C).  451 
 452 
2. IVD organ culture - mechanical effect of PU scaffold in nucleotomized IVD 453 
after 1 day of dynamic load 454 
The implanted PU scaffold was able to entrap water and swell in situ (Fig. 6 A), as 455 
indicated by weight increase of 301±33% and thickness increase of 103±15% already 456 
after 24 h culture in the IVD. 457 
After nucleotomy, the dynamic compressive stiffness modulus dropped to 30% 458 
compared with intact IVDs. After refilling the NP cavity with PU scaffold and free 459 
swelling culture overnight, the disc stiffness modulus was restored to 73±21% 460 
(p=0.073 vs. empty control). After dynamic load and free swelling recovery the 461 
stiffness modulus of PU scaffold refilled IVDs further increased to 82±14% (p<0.05 vs. 462 
empty control) (Fig. 6 B). Representative stress/strain curves of the empty control 463 
and PU scaffold refilled IVDs are shown in Figure 6 D and E respectively. 464 
Nucleotomy caused 3% decrease in disc height compared to intact IVDs. After 465 
dynamic load, IVDs implanted with PU scaffold maintained their disc height, while the 466 
disc height of empty controls further dropped by 7% (p<0.001 vs. implant group). 467 
After free swelling recovery overnight, the disc height of the implant group was 468 
restored to the level of the intact IVDs (p<0.001 vs. empty control) (Fig. 6 C). 469 
 470 
3. IVD organ culture – mechanical and biological effect of PU scaffold in 471 
nucleotomized IVD after 14 days of dynamic load 472 
3.1. Disc height change 473 
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After the 1st cycle of dynamic load, a disc height loss of -9.8 ± 2.3 % was noticed in 474 
partially nucleotomized IVDs compared with initial dimension of respective intact 475 
IVDs after dissection (Fig. 7 A; Empty Day 1). Implantation of PU scaffold restored 476 
disc height to -2.1 ± 0.5 % (Fig. 7 A; Scaffold Day 1; p<0.05 vs. Empty). After free 477 
swelling recovery, all the IVDs swelled and recovered to the height before load. The 478 
differences between partially nucleotomized IVDs and PU scaffold implanted IVDs 479 
were maintained. This diurnal disc height change pattern was observed during the 480 
entire period of 14 days repetitive dynamic load (Fig. 7 A).    481 
 482 
3.2. Gene expression  483 
After 14 days of culture with dynamic load, gene expression levels of NP and AF 484 
tissues were compared to the expression levels of disc tissues from respective 485 
bovine tails before starting organ culture on day 0 (Fig. 7 B and C). Compared with 486 
day 0, gene expression of IVD extracellular matrix components ACAN, COL2A1, 487 
COL1A2, BGN and Versican in partially nucleotomized IVDs (Empty) did not change 488 
significantly. Implantation of PU scaffold into the partially nucleotomized IVDs 489 
(Scaffold) also did not affect the expression level of these genes. Compared with 490 
healthy tissue of intact IVDs on day 0, gene expression of MMP13 in NP and AF 491 
tissues of partially nucleotomized IVDs increased 24-fold and 134-fold respectively 492 
after 14 days of culture with dynamic load. Implantation of PU scaffold into partially 493 
nucleotomized IVDs down-regulated the MMP13 gene expression in NP and AF by 8-494 
fold and 7-fold, respectively compared with Empty group.  495 
 496 
3.3. Biochemical analysis of disc tissue 497 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
GAG content, collagen content and proteoglycan synthesis rate per cell of native NP 498 
and AF tissues after 14 days of culture are shown in Table 4. In the remaining NP 499 
tissue after partial nucleotomy, GAG, collagen content and proteoglycan synthesis 500 
rate were not affected by implantation of the PU scaffold. In the AF tissue, neither 501 
GAG content nor collagen content per cell was affected by PU scaffold implantation. 502 
 503 
3.4. Histological analysis of whole IVDs  504 
Images of Safranin O/Fast Green stained sections of IVDs cultured for 14 days are 505 
shown in Fig. 8. The overview images (Fig. 8 A, C) clearly show that a partial 506 
nucleotomy was performed in the organ culture model. The swollen PU scaffold 507 
completely filled the nucleotomized region (Fig. 8 C). The envelope of the PU scaffold 508 
was observed as a ring in direct contact with the remaining disc NP tissue (Fig. 8 D). 509 
The remaining native disc NP tissue is still intensely stained with Safranin O after 14 510 
days of dynamic load. 511 
    512 
3.5. FTIR imaging analysis of discs tissue 513 
An example of an image reflecting the tissue distribution (sagittal direction) of a 514 
partially nucleotomized IVD cultured for 14 days under dynamic load without PU 515 
scaffold implantation is shown in Fig. 9 A. Tissue distribution maps of ROI of partially 516 
nucleotomized IVDs without (top) and with (bottom) PU scaffold implantation cultured 517 
for 14 days under dynamic load are shown in Fig. 9 B. The ROI tissue image of the 518 
empty IVD shows fissures caused by the nucleotomy and native tissue across the 519 
whole width of the IVD. The ROI tissue image of the PU implanted IVD shows a 520 
cavity in the center of the IVD where the implant was situated, surrounded by native 521 
disc tissue. Estimated component / tissue distribution line profiles of proteoglycan, 522 
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collagen type II and collagen type I across the IVD sections show distinctive trends, 523 
with proteoglycan and collagen type II profiles showing an overall increase and 524 
collagen type I profiles showing a decrease towards the NP region (Fig. 9 C). A 525 
comparison of the line profiles between the empty and PU scaffold implanted IVD 526 
shows very similar overall trends for proteoglycan, collagen type II and collagen type 527 
I. However, both proteoglycan and collagen type II show localized higher component 528 
to tissue ratios (sharp positive features) at around 25 %, 30 % and 67 % IVD width in 529 
the PU implanted IVDs. Collagen type I line profiles show localized lower component 530 
to tissue ratios (sharp negative features) at around the same areas (25 %, 30 % and 531 
67 % IVD width) in the PU implanted IVDs. 532 
 533 
Discussion 534 
The aim of this study was to develop a nucleus pulposus replacement material, which 535 
is feasible for non-invasive delivery and custom-made design, restores the 536 
mechanical property of nucleotomized IVDs and sustains cytocompatibility at the 537 
same time. The bi-phasic PU scaffold developed in this work has a flat discoid shape 538 
after manufacturing (Fig. 1 A front) and will swell after insertion into the IVD. Swelling 539 
rate is important for scaffold development and implementation, and enables the 540 
selection of the optimal core content. The PU scaffolds showed favorable in vitro 541 
swelling capability (Fig. 3 and Table 2) with a fast swelling rate (Fig. 4) post-hydration. 542 
Based on these results the extent of swelling could be tailored to the desired external 543 
scaffold dimensions. Hence a custom-made design is feasible depending on the 544 
individual geometry of NP material to be replaced. Implantation of the PU scaffolds 545 
into nucleotomized IVDs further confirmed the swelling capability of the PU scaffolds 546 
in situ. The implanted PU scaffolds expanded anisotropically to fill the nucleotomy 547 
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defect (Fig. 6 A and Fig. 8 C). In addition, stress relaxation tests revealed higher toe 548 
and linear modulus for these PU scaffolds than for human NP and no significant 549 
difference in percentage relaxation between the PU scaffold and human NP, further 550 
indicating the suitability of the material for NP replacement (unpublished results from 551 
consortium partner). 552 
The cytocompatibility of the PU scaffold was assessed with NP cells and bone 553 
marrow derived MSCs. Viable cell numbers after culturing in the conditioned medium 554 
from the core or the envelope material were higher than 85% of cell numbers after 555 
culture in control  medium (Fig. 5 A and B). In addition, NP cells were seeded on top 556 
of the outer envelope material, and presented effective adhesion after 1 day and 557 
active cell proliferation and extracellular matrix synthesis after 7 days (Fig. 5 C). 558 
These results indicate that the cytocompatibility of the PU scaffolds is advantageous 559 
with respect to both NP cells and MSCs. Another interesting finding is that the 560 
conditioned medium of the core material stimulated MSC growth compared to the 561 
control medium. The underlying reason of this observation should be further 562 
examined in future studies. 563 
The main challenge in developing an NP replacement material is to immediately 564 
restore the mechanical property in a nucleotomized IVD. Emerging numbers of NP 565 
replacement devices/biomaterials have been tested for their mechanical restoration 566 
effect in nucleotomized IVDs [9, 34-37]. However, all the materials were tested in ex 567 
vivo or in vivo nucleotomy models with an incision through the AF. Reitmaier et al. 568 
compared two annulus closure methods after NP replacement with the native NP 569 
tissue removed during nucleotomy. They found that the disc height loss and disc 570 
stiffness differ between the two conditions. This demonstrates that the preservation of 571 
the disc’s mechanical function following NP replacement is partially dependent on the 572 
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quality of the closure of the annulus defect [38]. This may also explain some failures 573 
of NP replacement materials in the case of dislocation or protrusion through the AF 574 
incision. To assess the mechanical repair effect of the NP replacement material 575 
solely, an alternative nucleotomy approach in organ culture was used in this study, 576 
whereby an incision was made through the endplate while preserving an intact 577 
annulus (Fig. 6 A right) [22]. This model is highly useful for evaluation and screening 578 
NP replacement materials in whole organ culture under load before pre-clinical in 579 
vivo testing.  580 
In the current study, partial nucleotomy through the endplate in the organ cultured 581 
IVD substantially altered the mechanical property of the IVD, as indicated by a 70% 582 
reduction in the axial stiffness (Fig. 6 B). Implantation of the PU scaffold significantly 583 
restored the axial stiffness and disc height of the nucleotomized IVD after cyclic 584 
dynamic load and recovery culture (Fig. 6 B and C). The restoration in axial stiffness 585 
and disc height occurred relatively fast, already after the first cycle of 3 hours load, 586 
which indicates an immediate repair effect. Furthermore, the disc height restoration 587 
was maintained through 14 days of repetitive dynamic load and recovery culture (Fig. 588 
7 A), which indicates that the PU scaffolds implanted in situ are able to restore the 589 
mechanical property of a nucleotomized IVD in organ culture. In our previous study 590 
[22], a fibrin-hyaluronan hydrogel was delivered into nucleotomized IVD and the 591 
mechanical repair function was assessed with the same method. It was found that 592 
the fibrin-hyaluronan hydrogel restored the disc height after dynamic loading, but not 593 
the dynamic compressive stiffness of the nucleotomized IVD. These results 594 
demonstrate that the PU scaffolds developed in this study are superiorly able to 595 
restore the mechanical function of the nucleotomized IVD compared to a biomimetic 596 
hydrogel. In the current study, the mechanical characterization was focused on the 597 
compressive modulus and the disc height change. The assessment of the 598 
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viscoelastic parameters and the neutral zone of the IVD before and after scaffold 599 
implantation will also be of interest for us in future studies to explore the effects of the 600 
scaffolds in more detail. 601 
Another advantage of our organ culture model is that the IVDs can be maintained 602 
viable under dynamic load in a bioreactor for several weeks [25], after which the 603 
biological property of the nucleotomized IVDs with/without NP replacement can be 604 
assessed. In this study, after 14 days culture with dynamic load, we investigated the 605 
phenotype of the disc cells, the extracellular matrix components, and the structure of 606 
the disc tissue in nucleotomized IVDs with/without implanted PU scaffold. In 607 
nucleotomized IVDs without NP replacement, the MMP13 gene expression level of 608 
the cells in the AF tissue and remaining NP tissue increased dramatically after 14 609 
days of culture (Fig. 7 B and C), which demonstrates an increase in catabolic signals 610 
in the disc tissue. MMP13 is known to be overexpressed in cartilage from patients 611 
with osteoarthritis compared with healthy cartilage [39]. The expression and activity 612 
of MMP13 are also increased during disc degeneration [40]. This indicates that a IVD 613 
after partial nucleotomy is prone to a degenerative pathology in the remaining native 614 
disc tissue. Implantation of the PU scaffold into the nucleotomized IVD markedly 615 
down-regulated the MMP13 expression in the NP and AF tissues (Fig. 7 B and C). 616 
This may slow down further degeneration of the native disc tissue compared with the 617 
unrepaired IVD.  618 
The content and distribution of proteoglycan and collagen in the disc tissue were 619 
analyzed by biochemical measurement, Safranin O/Fast Green staining, and FTIR on 620 
disc sections. The disc matrix composition was not changed significantly in the NP 621 
and AF regions of the IVDs in the presence of the PU scaffold. However, in the native 622 
NP tissue surrounding the implanted PU scaffold, proteoglycan and type II collagen 623 
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showed localized higher expression, while type I collagen showed localized lower 624 
expression compared with the nucleotomized IVD without repair (Fig. 9 C). This 625 
indicates that the implanted PU scaffold is beneficial in maintaining the NP cell 626 
phenotype in the surrounded disc tissue.  627 
The underlying reason for the above mentioned biological changes is likely to result 628 
from the restoration in the geometry and load pressure on the remaining native disc 629 
tissue. In the nucleotomized IVD without repair, the remaining disc tissue swells into 630 
the nucleotomized region. Therefore, the tissue is less compact and the pressure on 631 
the tissue is disturbed. The implantation of the PU scaffold decreased the native 632 
tissue volume in the disc space by occupying the NP cavity, which is likely to lead to 633 
a higher local intensity of proteoglycan and type II collagen. Furthermore, the 634 
implanted PU scaffold restored the pressure in the nucleotomized region and the 635 
stiffness of the IVD, therefore the remaining disc tissue experienced higher load 636 
pressure compared with the tissue in the non-repaired IVD. Our previous study has 637 
shown that dynamic load down-regulated the MMP13 gene expression level in AF 638 
tissue and COL1 gene expression level in NP tissue from organ cultured IVD 639 
compared with free swelling condition [27]. Other ex vivo studies also revealed that 640 
dynamic load preserves disc cell phenotype compared to unloaded or static load 641 
condition [41, 42]. Taken together, these data corroborate that mechanical pressure 642 
is essential to maintain the function and homeostasis of the disc tissue. The PU 643 
scaffold developed in this study, as an NP replacement material, can rebalance the 644 
pressure in the nucleotomized IVD and has the potential to prevent further 645 
degeneration of the remaining disc tissue. 646 
The dry PU scaffolds can be rolled into a tube and delivered through a needle with 647 
insertion guide (Fig. 1 C). Such injectable design allows less invasive delivery 648 
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compared to the mechanical NP replacement devices, including NUBAC™ [43], 649 
REGAIN™ [34], and BUCK™ [9]. Furthermore, a transpedicular approach has 650 
recently been developed to deliver therapeutic factors to the IVD without further 651 
damage to the AF [44, 45]. With this approach, our PU scaffolds could be delivered 652 
through the pedicle and the endplate to the NP while preserving the mechanical 653 
function of AF in cases of early disc degeneration with an intact annulus. In case of 654 
patients with AF defects, proper AF closure approach is needed to prevent herniation 655 
of the implanted NP replacement material. Suture [46] and glue [47, 48] may be 656 
sufficient to close small annular defects. For large annular failure, tissue engineered 657 
material mimicking native AF tissue may be needed to fully restore the mechanical 658 
property of the AF [27]. Regardless of mechanical properties, the nucleotomy 659 
approach through the endplate might also induce a biological degenerative cascade 660 
according to literature data. Damage of the EP by drilling has been shown to 661 
decrease the water content in the outer AF and proteoglycan content in the NP [49] 662 
and may trigger Schmorl's nodes [45]. Further investigation to optimize the 663 
transpedicular approach is essential to fully reach the requirements of a safe, non-664 
invasive, and functional NP replacement therapy. 665 
Limitations of the current study remain in the following aspects: 1) the PU scaffolds 666 
were assessed in nucleotomized IVD under healthy conditions; hence exposure to 667 
the pathological environment occurring in a degenerative IVD is lacking; 2) the ex 668 
vivo organ culture model differs from in vivo conditions where additional systemic 669 
responses may arise. More research work will therefore be necessary to assess the 670 
effects of the material before clinical translation can be considered. Whole organ 671 
culture models mimicking IVD degeneration through enzymatic treatment of the NP 672 
[50, 51], high frequency mechanical loading [52], or addition of pro-inflammatory 673 
cytokines [53] may be used to evaluate the material under pathological conditions. 674 
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Ultimately, in vivo large animal models would provide further insight into the delivery, 675 
stability and effect of the PU scaffolds for NP replacement at longer term after 676 
implantation. 677 
 678 
Conclusions 679 
In this study, an injectable and cytocompatible bi-phasic PU scaffold was developed 680 
for NP replacement. The implant was assessed in whole organ culture under 681 
dynamic load for its mechanical and biological repair effect in nucleotomized IVD. 682 
The nucleotomy model through the endplate enabled pure assessment of the PU 683 
scaffold, independent of the closure method for an annulus incision. The designed 684 
PU scaffold with swelling capacity in situ is able to restore the mechanical property of 685 
nucleotomized IVDs, and shows potential to retard further degeneration of native disc 686 
tissue. This work provides a new approach to facilitate future progress in the 687 
development of an NP replacement material, and the screening of materials using 688 
whole organ culture. The bi-phasic PU scaffold developed in the current study 689 
warrants further pre-clinical investigation to evaluate its potential for functional, non-690 
invasive and custom designed NP replacement. 691 
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Table 1. The effect of Chronoflex™ (CF) : Hydromed™ (HM) w/w ratio on the 
function of the envelope material. 
Experimental 
Group 
CF:HM w/w 
ratio 
Tensile Strength 
(N/mm2) 
Wetting time 
(minutes) 
1 1:0 5.32 300 
2 15:1 5.31 210 
3 12:1 4.80 30 
4 10:1 4.71 18 
5 9:1 4.65 5 
6 8:1 4.28 5 
7 6:1 4.1 2 
8 4:1 3.7 1 
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Table 2. Oligonucleotide primers and probes (bovine) used for real-time PCR. 
Gene Primer/probe type Sequence 
COL1A2 Primer fw (5'-3') 
Primer rev (5'-3') 
Probe (5'FAM/3'TAMRA) 
TGC AGT AAC TTC GTG CCT AGC A 
CGC GTG GTC CTC TAT CTC CA 
CAT GCC AAT CCT TAC AAG AGG CAA CTG C 
COL2A1 Primer fw (5'-3') 
Primer rev (5'-3') 
Probe (5'FAM/3'TAMRA) 
AAG AAA CAC ATC TGG TTT GGA GAA A 
TGG GAG CCA GGT TGT CAT C 
CAA CGG TGG CTT CCA CTT CAG CTA TGG 
ACAN  Primer fw (5'-3') 
Primer rev (5'-3') 
Probe (5'FAM/3'TAMRA) 
CCA ACG AAA CCT ATG ACG TGT ACT 
GCA CTC GTT GGC TGC CTC 
ATG TTG CAT AGA AGA CCT CGC CCT CCA T 
MMP13 Primer fw (5'-3') 
Primer rev (5'-3') 
Probe (5'FAM/3'TAMRA) 
CCA TCT ACA CCT ACA CTG GCA AAA 
GTC TGG CGT TTT GGG ATG TT 
TCT CTC TAT GGT CCA GGA GAT GAA GAC CCC 
ACAN: aggrecan; COL1A2: collagen type I; COL2A1: collagen type II; MMP13: matrix 
metalloproteinase 13; fw: Forward; rev: Reverse; FAM: Carboxyfluorescein; TAMRA: 
Tetramethylrhodamine 
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Table 3. Swelling capacity (at saturation) of PU scaffolds with various sizes in 
aqueous media, Mean ± SD. 
 
Core content 
(mg) 
Scaffold 
diameter 
(mm) 
Increase in scaffold weight 
(% of initial) 
Increase in core weight  
(% of initial) 
3.4 (n=10) 6 409.96% ± 21 825.68% ± 34 4.5 (n=6) 444.49% ± 25 769.40% ± 17 
12 (n=5) 8 563.07% ± 26 783.01% ± 40 
12 (n=10) 9 559.22% ± 18 847.85% ± 20 
40 (n=7) 14 635.40% ± 13 846.20% ± 25 
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Table 4. Biochemical analysis of native disc tissue in partially nucleotomized IVDs 
without/with PU scaffold implantation after 14 days of dynamic load. Total 
glycosaminoglycan (GAG) content, total collagen content and proteoglycan (PG) 
synthesis rate were measured and normalized to the DNA content of the respective 
samples. Empty – partially nucleotomized IVD, Scaffold – partially nucleotomized IVD 
implanted with PU scaffold. GAG/DNA ratio in µg / µg; Collagen/DNA ratio in µg / µg, 
PG/DNA in counts per minute (CPM) / µg; PG/DNA was performed for NP tissue 
only. Mean ± SD, n=6.   
Biochemical analysis of disc tissue 
NP tissue 
Group Empty Scaffold 
GAG / DNA 1151.6 ± 224.7 1166.8 ± 369.1 
Collagen / DNA 639.9 ± 474.3 1017.2 ± 944.5 
PG / DNA 98.4 ± 45.1 79.1 ± 50.2 
 
AF tissue 
Group Empty Scaffold 
GAG / DNA 628.9 ± 348.1 502.8 ± 281.2 
Collagen / DNA 1070.4 ± 653.9 1276.8 ± 640.6 
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Figure Legends 
 
Figure 1. (A) Flat discoid shaped PU scaffold before (front) and after (back) swelling 
at various sizes (from left to right 6, 9 and 14 mm). Each size has defined core 
content.  (B) Scheme of PU scaffold assembly process: core disc is wrapped by two 
envelope discs, and heat sealed within a custom made sealing mold. (C) Non-
invasive delivery system for PU scaffold: a demonstration of the scaffold insertion 
and swelling function after delivery and hydration. 
 
Figure 2. SEM micrographs of electrospun PU scaffold envelope. Magnifications: left 
2,000x; right 10,000x. Scale bar: left 50 µm, right 10 µm. 
 
Figure 3. Swelling of PU scaffolds after 24 hours incubation in aqueous media tested 
at different core contents. Scaffold size: 14 mm in diameter. 
 
Figure 4. Swelling kinetic of PU scaffolds at a diameter of 14 mm (A) and 6mm (B). 
For each scaffold diameter different amounts of core material were tested. Mean ± 
SD, n=3. 
 
Figure 5. (A-B) Cell number after culture in core and envelope conditioned media 
measured by WST-1 assay and normalized to positive control (cells cultured with 
DMEM/2.5% FBS). Mean ± SD, n=3. (A) NPCs and MSCs cultured in conditioned 
medium of core for 24 hours or 72 hours. (B) NPCs and MSCs cultured in 
conditioned medium of envelope for 24 hours or 72 hours. (C) Representative SEM 
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images showing morphological structures of top surface and cross section of cell-
seeded envelope constructs after 1 or 7 days of culture. 
 
Figure 6. (A) Left: Macroscopic view of dry PU scaffold (diameter 6 mm) before 
implantation into partial nucleotomized IVD. Middle: Macroscopic sagittal view of 
partial nucleotomized IVD. Right: Macroscopic sagittal view of partial nucleotomized 
IVD with implanted PU scaffold after 24 hours of culture. PU scaffold swelled in situ 
and completely filled the nucleotomized region.  (B) Dynamic compressive stiffness 
modulus of partial nucleotomized IVD before (defect) and after (refilled) refilling with 
PU scaffold, and after dynamic load and free swelling recovery (after dynamic load 
and recovery). Data were normalized to the stiffness modulus of respective intact IVD. 
(C) Disc height change of IVDs after dissection and free swelling culture overnight 
(intact), after partial nucleotomy (defect), after refilling with PU scaffold and free 
swelling culture overnight (refilled), after dynamic load (after dynamic load), and after 
free swelling recovery (after recovery). Data were normalized to initial disc height 
after dissection. (D and E) Representative stress/strain curves of IVDs from Empty 
and Scaffold groups at different time points. Mean ± SD, n=6, * p<0.05, *** p<0.001 
Empty versus Scaffold. Empty – partially nucleotomized IVDs, Scaffold – partially 
nucleotomized IVDs with implanted PU scaffold. 
 
Figure 7. (A) Disc height change of partially nucleotomized IVDs without/with PU 
scaffold implantation under repetitive dynamic load. Mean ± SD, n=6, *p<0.05, 
**p<0.01, ***p<0.001 Empty versus Scaffold. (B-C) Relative mRNA expression of 
cells from remaining native NP and AF tissue in nucleotomized IVDs without/with PU 
scaffold implantation after 14 days of dynamic load. Data were normalized to the 
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gene expression level of disc tissue from respective bovine tail before starting organ 
culture on day 0. Mean + SD, n=8. Empty – partially nucleotomized IVDs, Scaffold – 
partially nucleotomized IVDs with implanted PU scaffold. 
 
Figure 8. Representative Safranin O/Fast Green stained transverse sections of 
partially nucleotomized IVDs without/with PU scaffold implantation after 14 days of 
culture under dynamic load. (A, C) Overview of IVD without/with PU scaffold 
implantation, scale bar: 1000 μm. (B, D) Interface between remaining NP tissue and 
nucleotomized region without/with PU scaffold implantation, scale bar: 50 μm. Empty 
– partially nucleotomized IVDs, Scaffold – partially nucleotomized IVDs implanted 
with PU scaffold, s – PU scaffold, t – native disc NP tissue. 
 
Figure 9. Representative FTIR tissue distribution map of a sagittal section of a 
partially nucleotomized IVD cultured for 14 days under dynamic load without PU 
scaffold (empty) (A). Image contrast for tissue distribution map is generated by 
integration of the 2nd derivative of the Amide III peak (1186-1297 cm-1). The black 
square indicates a region of interest (ROI) which was used to investigate the matrix 
distribution of native disc tissue surrounding the implants cavity. FTIR tissue 
distribution maps of ROIs of an empty IVD (top) and an IVD implanted with the PU 
scaffold (bottom) cultured  for 14 days under dynamic load  (scale bar: white to black 
indicative of a low to high tissue content) (B). Estimated component per tissue 
distribution line profiles across the ROI normalised to 100 % IVD width of 
proteoglycan, collagen type II and collagen type I are shown for an empty IVD and a 
PU scaffold implanted IVD (C).  
 
